Skip to main content

Lung Abscess

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Biomarkers for Diagnosis of Lung NodulesN/A1 trial
Active Trials
NCT01085864Active Not Recruiting550Est. Oct 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Colorado TherapeuticsBiomarkers for Diagnosis of Lung Nodules

Clinical Trials (1)

Total enrollment: 550 patients across 1 trials

NCT01085864Colorado TherapeuticsBiomarkers for Diagnosis of Lung Nodules

Biomarkers for Diagnosis of Lung Nodules

Start: Mar 2010Est. completion: Oct 2027550 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.